{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Kaiser Permanente, one of the nation's largest managed care organizations, has ordered its pharmacies to stop dispensing Bextra, an arthritis and pain drug made by Pfizer that some tests have indicated may increase the risk of heart attacks and strokes. Bextra is in the same class of drugs as another Pfizer painkiller, Celebrex, which has also been found to pose cardiac risks at high doses, and as Vioxx, the drug that Merck pulled from the market last fall after its own tests disclosed cardiac risks.", "headline": {"main": "Big Health Plan Suspends Use Of Painkiller"}, "abstract": "Kaiser Permanente, one of nation's largest managed care organizations, orders its pharmacies to stop dispensing Bextra, arthritis and pain drug made by Pfizer that some tests have indicated may increase risk of heart attacks and strokes; Bextra is same class of drugs as another Pfizer painkiller, Celebrex, which has also been found to pose cardiac risks at high doses, and as Vioxx, drug that Merck pulled from market last fall after is own tests disclosed cardiac risks; SEC opens formal investigation of Merck's handling of issues related to Vioxx; suspension of Bextra is first case of Kaiser's doctors deciding to ban use of drug that has been approved by FDA (M)", "print_page": "1", "word_count": 768, "_id": "4fd24a488eb7c8105d7e80e2", "snippet": "Kaiser Permanente has stopped dispensing Bextra, an arthritis and pain drug made by Pfizer that may increase the risk of heart attacks and strokes.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/01/29/business/29drugs.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "KAISER PERMANENTE"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "PFIZER INC"}, {"name": "organizations", "value": "MERCK & CO"}, {"name": "organizations", "value": "PFIZER INCORPORATED"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "CELEBREX (DRUG)"}, {"name": "subject", "value": "BEXTRA (DRUG)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PAIN"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "COX-2 INHIBITORS (DRUGS)"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Gardiner", "rank": 1, "lastname": "HARRIS"}], "original": "By GARDINER HARRIS"}, "document_type": "article", "pub_date": "2005-01-29T00:00:00Z", "section_name": "Health; Business"}], "meta": {"hits": 1, "offset": 0, "time": 40}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}